Lux Biosciences to Present at Lazard Capital Markets 6th Annual Healthcare Conference
11/16/2009 9:34:46 AM
More...
|
Potential of Lux Biosciences' LUVENIQ (LX211) as First Disease Modifying Treatment for Sight-Threatening Non-Infectious Uveitis Highlighted at American Academy of Ophthalmology
10/26/2009 9:10:11 AM
More...
|
Lux Biosciences Announces Multiple Presentations on LX211 at Upcoming American Academy of Ophthalmology and American Uveitis Society Annual Meetings
10/20/2009 9:24:27 AM
More...
|
Lux Biosciences Completes $50 Million Series B Financing
10/19/2009 6:19:00 AM
More...
|
Lux Biosciences Reports Phase 1 Safety Results and Open Label Efficacy Results for LX214, a Potential Best-in-Class Treatment for Dry Eye
9/23/2009 9:10:03 AM
More...
|
Lux Biosciences to Present at the Thomas Weisel Partners Health Care Conference
9/8/2009 9:11:07 AM
More...
|
Lux Biosciences' Luveniq(TM) (LX211) Highlighted at International Conference on Ocular Inflammation
5/26/2009 10:24:40 AM
More...
|
First Oral Drug for Uveitis Reduces Both Inflammation and Recurrence Rate in Potentially Blinding Eye Disease, Reports Lux Biosciences
5/5/2009 9:39:05 AM
More...
|
Lux Biosciences Announces Positive Phase 3 Uveitis Trial Results for Voclosporin
3/26/2009 7:26:22 AM
More...
|
Lux Biosciences Completes Patient Enrollment in LUCIDA Phase 3 Program for Prevention of Corneal Transplant Rejection
3/18/2009 10:50:38 AM
More...
|
|